BAMCO Inc
ARQT icon

BAMCO Inc’s Arcutis Biotherapeutics ARQT Stock Holding History

BAMCO Inc’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.9M Buy
1,253,120
+180,931
+17% +$4.22M 0.05% 175
2026
Q1 		$25.3M Buy
1,072,189
+567,489
+112% +$14.5M 0.08% 177
2025
Q4 		$14.7M Buy
+504,700
New +$12.9M 0.04% 215

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BAMCO Inc's ARQT Position: Q2 2026 in Review

BAMCO Inc increased its Arcutis Biotherapeutics (ARQT) stake by 17% in Q2 2026, buying an estimated $4.22M and bringing the position to 1,253,120 shares worth $32.9M. The position accounts for 0.05% of the portfolio, ranked #175.

BAMCO Inc first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • BAMCO Inc held 1,253,120 shares of Arcutis Biotherapeutics worth $32.9M as of Q2 2026.
  • BAMCO Inc bought 180,931 Arcutis Biotherapeutics shares in Q2 2026, an estimated $4.22M.
  • Arcutis Biotherapeutics made up 0.05% of BAMCO Inc's portfolio in Q2 2026, its #175 holding.
  • BAMCO Inc first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on BAMCO Inc's 13F filing for Q2 2026, filed 14 Aug 2026.